![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, September 02, 2018 4:54:56 PM
I challenge you to compare the number of subjects in the Otezla Phase 2 trial to the number of subjects in the previous Prurisol Phase 2 trial.
For the Phase 2 Otezla trial CC-10004-PSOR-004
...It is important to note that the proportion of subjects achieving PASI-75 (30%) is similar to the 24.3% seen in Study CC-10004-PSOR-003, where subjects could not enter the trial if they had failed therapy with cyclosporine pr biologic therapy....
https://media.celgene.com/content/uploads/CC-10004-PSOR-004-Synopsis-Redacted.pdf
Compare Otezla to Prurisol
Within just 84 days 46% of patients receiving 200mg per day of Prurisol with “moderate” psoriasis achieved IGA 0/1
THAT IS AMAZING!!!
What do you expect for those that took 300 mg per day (150 mg every 12 hours) or 400 mg per day (200 mg every 12 hours)?
My guess is that for Prurisol 150 mg BID the percentage of subjects that achieve PASI 75 will be 67% +/- 15% (52%-82%) or better.
https://clinicaltrials.gov/ct2/show/NCT02494479?term=NCT02494479&rank=1
![](http://investorshub.advfn.com/uimage/uploads/2018/9/2/kmyisslide24_from_nov_2016.jpg)
https://static1.squarespace.com/static/5715352e20c647639137f992/t/583ddc8303596e5fc7e8bf06/1480449160455/Cellceutix_Corporate_Slide+Deck_DERMATOLOGY_November+2016+Website+Vers.pdf
Good luck and GOD bless,
George
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM